Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Close this folderAnnex 1: Research proposal
View the documentI. Introduction
View the documentII. The Problem
View the documentIII. Research Question and Objectives of Proposed Study
View the documentIV. Study Approach
View the documentV. Anticipated Outcomes
View the documentVI. Methods
View the documentVII. Time Line and Resources
View the documentSelected References
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series
 

IV. Study Approach

The project will have three phases: planning, research and dissemination. The research phase is described in this section; for details of the planning and dissemination phases, see Section 7 below.

The research phase will evaluate national drug policies in 8 developing countries, and will produce a series of country studies that examine key processes of policy formulation and implementation. The research will combine summative and formative evaluation strategies (see Background Paper). Both quantitative and qualitative measures and approaches (described below) will be used in carrying out the analysis.

The 8 countries selected for this project are: Colombia, Guinea, India, Philippines, Sri Lanka. Vietnam, Zambia, and Zimbabwe. These developing countries from Africa, Asia, and Latin America have been chosen based on the following criteria: socio-economic status, political system and regime type, geographical and demographic factors, colonial history, existence or absence of a formal NDP, public-private mix and size of domestic pharmaceutical industry, availability of in-country contacts, and the existence of previous studies. They include some of the world's poorest countries, as well as some middle-income countries; countries with no pharmaceutical manufacturing capacity, as well as some with substantial capacity.

The implementation of the research phase of the project will involve:

1: Assessment of NDP performance, through the application of a standard set of indicators, in order to evaluate NDP outcomes as well as processes.

2: Two rounds of group evaluation as a means for a) Achievement of group consensus on methodologies, and the training of the country team coordinators (Round 1). and b) a comparative analysis of strengths and weaknesses of NDPs, and identifying key questions for the political mapping (Round 2).

3: Analysis of the NDP formulation and implementation processes, through the application of political mapping, in order to assess organizational and political variables. A second round of political mapping may be undertaken in a subset of the study countries, aimed at addressing specific questions that emerge from the first round of evaluations and political mapping.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014